KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vir Biotechnology (VIR) Operating Expenses (2018 - 2025)

Vir Biotechnology's Operating Expenses history spans 8 years, with the latest figure at $112.0 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 13.54% year-over-year to $112.0 million; the TTM value through Dec 2025 reached $547.9 million, down 17.16%, while the annual FY2025 figure was $547.9 million, 17.16% down from the prior year.
  • Operating Expenses for Q4 2025 was $112.0 million at Vir Biotechnology, down from $173.7 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $241.0 million in Q4 2021 and bottomed at $112.0 million in Q4 2025.
  • The 5-year median for Operating Expenses is $167.7 million (2024), against an average of $171.9 million.
  • The largest annual shift saw Operating Expenses surged 118.82% in 2021 before it plummeted 33.86% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $241.0 million in 2021, then fell by 17.05% to $199.9 million in 2022, then dropped by 22.06% to $155.8 million in 2023, then dropped by 16.87% to $129.5 million in 2024, then decreased by 13.54% to $112.0 million in 2025.
  • Per Business Quant, the three most recent readings for VIR's Operating Expenses are $112.0 million (Q4 2025), $173.7 million (Q3 2025), and $119.6 million (Q2 2025).